New Research looking at Diabetic Macular Oedema and the Importance of Vascular Endothelial Growth Factor Therapies in its Treatment

4 August 2014 — Diabetic macular oedema (DMO) is a major cause of blindness worldwide and its incidence is increasing due to the greater numbers of people with diabetes. The disease is a result of changes in retinal capillaries that leak and changes in the retinal pigment epithelium causing macular thickening, oedema and poor eyesight, leading to vision loss if left untreated. DMO is particularly serious due to its onset
affecting a young/middleaged age group and disabling them during their productive working lives.